← Tüm fırsatlar

Horizon Europe · Avrupa Birliği

Advancing bio-printing of living cells for regenerative medicine

3 Haziran 2027 tarihinde açılıyor

AB Ufuk Avrupa programı tarafından 4 hibe bekleniyor; proje başına €7 milyon – €10 milyon; toplam bütçe €39,3 milyon. Başvurular 16 Eylül 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.

Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.

Beklenen sonuçlar

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes:

• Biomedical scientists from academia and industry will gain access to entire bio-printing units designed to regenerate human tissue.

• Healthcare professionals acquire information on the safe and effective use of equipment enabling advanced therapies with bio-printed human tissue.

• Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need.

• Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.

Kapsam

Tissue-specific functional 3D bio-printing of living cells has made significant progress as a new approach for transplantation applications in regenerative medicine. There are currently several types of bio-printing technologies under development for the repair of different targeted tissues or organs. To fully unleash the potential of bio-printed cell constructs for regenerative medicine several bottlenecks still need to be overcome. Various studies in pre-clinical models have shown that bio-printed cell constructs or tissues hold great promise for regenerative medicine, by allowing autologous tissue grafts being printed thus avoiding adverse graft-host reactions. However, translation of such approaches into clinical settings (i.e. humans) and their application to internal organs still needs to be investigated and demonstrated. Dependant on the actual target site (i.e. the defect tissue or organ in the human body) different bio-printing approaches may be preferable. For printing complex tissues and especially entire organs an in-vitro approach followed by transplantation is the preferred way. “In-situ” bio-printing, sometimes also referred to as “in-vivo”, or as “intraoperative”, reflects a bioprinting process performed on a live subject in a surgical setting and has in certain instances (e.g. tissue repair) advantages over an in-vitro bio-printing technique followed by transplantation. In-situ bio-printing involves direct patterning of bio-inks onto a patient’s body at the target site, allowing for precise construction of a site-matching tissue-structure within the actual physiological location where regeneration or repair is needed. As such, in-situ bio-printing allows for high adaptability, reduced risk of contamination, improved cell viability, function and host integration. The high cell densities present in the human vital organs underscore the importance of bio-inks which contain less additional biomaterials as matrix. Hence the bio-printing of cell constructs that comprise native tissue-like cell densities may facilitate repair and/or regeneration of defective complex tissues or internal organs. For such approaches meticulous engineering of the bio-printing equipment is necessary, involving sophisticated micro-surgical instrumentation and medical imaging platforms. To achieve the desired function and to mimic the natural cues in native tissues for in-vitro printed bio-constructs, the use of additional stimuli is needed, whereas in-situ approaches normally rely on the body as natural bioreactor providing the necessary extracellular cues. Recently, combinations of in-situ bio-printing with real-time stimuli have been investigated, even for the repair of internal organs. However, there remain bottlenecks that need to be overcome, like the integration with existing imaging modalities and surgical procedures or the long-time stability and functionality of the created bio-constructs.

Kimler başvurabilir

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.

Konular

Biomaterial engineering Biomedical engineering Health-related biotechnology Personalised treatment Regenerative medicine Tissue engineering ATMP Bio-Ink Bio-Printing Biofabrication Bioink Biomaterials Bioprinting In-Situ Bio-Printing Regenerative Medicine Scale-Up Tissue Engineering

Zamanlama

Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

Nasıl başvurulur

1. Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
2. Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
3. İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
4. Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
5. Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.

From the call text

Who can apply

Not stated in the call text we hold — check the official page

Company stage

Not stated in the call text we hold — check the official page

Single applicant or consortium

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where applicants must be based

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

Where to apply

Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

AB başvuru rehberini okuyun

Resmi kaynaklar

Resmi çağrı sayfası

Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.

Horizon Europe: diğer çağrılar